Financial Performance (9M 2023 Figures Unless Otherwise Stated, Growth Numbers At CER)
‒ Total Revenue $33,787m, up 5% despite a decline of $2,896m from COVID-19 medicines[6]
‒ Excluding COVID-19 medicines, both Total Revenue and Product Sales increased 15%
‒ Total Revenue from Oncology medicines increased 20%, CVRM[7] 19%, R&I[8] 9%, and Rare Disease 12%
‒ Core Product Sales Gross Margin[9] of 82%, up two percentage points, reflecting the decline in sales of lower margin COVID‑19 medicines
‒ Core Operating Margin of 35% increased by three percentage points including the previously-announced gain from an update to the contractual relationships for Beyfortus, totalling $712m and recorded in Core Other operating income
‒ Core EPS increased 17% to $5.80
‒ FY 2023 Total Revenue excluding COVID-19 medicines now expected to increase by a low-teens percentage at CER
‒ FY 2023 Core EPS now expected to increase by a low double-digit to low-teens percentage at CER
https://www.investegate.co.uk/announcem ... ts/7869792
Ian (I hold).